Moreover as evidenced previously in ovarian cancer lines [41] and triple negative breast cancer [23], as well as in this study, CDK9 expression can be downregulated by dinaciclib, which may explain the observed augmentation of EV-T responses by the inhibitor. Here, CDK9 is linked to ovarian carcinoma.